CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-based Cas, DNA-free Cas), By Application (Biomedical, Agriculture), By End Use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global CRISPR and cas genes market size was valued at USD 1.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.7% from 2021 to 2028. 2020 was a remarkable year for the market as the Nobel Prize in Chemistry was received by Emmanuelle Charpentier and Jennifer A. Doudna for the breakthrough research in CRISPR/Cas9 genetic scissors for genome editing, thereby positively impacting the market.

Furthermore, the development of CRISPR-based diagnostic tests to address the timeline and sample collection challenges for COVID-19 screening is driving the market. The tests are designed to offer advantages such as high precision and sensitivity, rapid detection, no requirement of special laboratory equipment, and portability. For instance, in December 2020, researchers from Gladstone Institutes developed a CRISPR-based test that uses smartphones to deliver results.

Apart from this, the technological advancements in CRISPR/Cas9 system have revolutionized the area of cancer research and treatment. This has become the mainstream methodology used in many cancer biology studies. In addition, in March 2021, the U.S. FDA approved clinical trial testing for a CRISPR-based gene therapy product, designed to treat genetic defects resulting in sickle cell disease. This trial will be led by researchers from the University of California San Francisco and UC Berkeley. 

Furthermore, competition among the existing players has increased owing to technological developments and their potential applications. There has been an increased focus on the highly adaptable CRISPR technology. For instance, as of May 2020, Merck KGaA has received a total of 26 CRISPR patents worldwide. This indicates the increasing focus of biotechnology companies on CRISPR/Cas gene technology.

The CRISPR and Cas gene-based genome editing applications are more or less in a nascent stage of development and a considerable number of possible usages are still unchartered. These areas can later be a source of the significant untapped potential provided that specific product-based commercialization picks up the pace that numerous investors in the market are anticipating.

Product and Service Insights

The product segment dominated the market and accounted for the largest revenue share of 79.4% in 2020. The presence of innovative tools and CRISPR gene editing kits for gene modification experiments addresses the growing demand for genome editing solutions. In addition, the availability of enhanced individual products to serve multiple objectives like specific genome cleavage, genome engineering, reduced off-target cutting, easy gene knockouts, and increased specificity are supportive for the estimated share.

Furthermore, rising investments in gene editing-based R&D along with the emergence of novel applications are expected to drive the market. For instance, the application of DNA-free Cas9, especially in grapevine and apple protoplasts, rice lettuce, and tobacco is expected to support the projected growth in the coming years.

This segment of the market is expected to generate higher revenue over the forecast period as many of the researchers working on gene editing are adopting these products. On the other hand, cell line engineering services are the most common services provided by CRISPR-based gene editing companies. The companies are leveraging this technology to engineer a wide range of CRISPR cell line models with several gene or locus-specific modifications.

Application Insights

The biomedical applications segment dominated the market and accounted for the largest revenue share of 92.8% in 2020. Increasing implementation of CRISPR gene-editing tools in several areas of biomedical sciences has majorly contributed to the high revenue of this segment. Extensive research in the biomedical field is expected to drive the segment throughout the forecast period.

In addition, the implementation of nano-carriers and the introduction of improved delivery systems have significantly enhanced the efficacy and the specificity of this technology. The advent of CRISPR/Cas9 nuclease allows easy & precise genome editing. Thus, the gene and cell therapy arena would directly impact the use of CRISPR genome editing technology.

Besides, the incorporation of innovative breeding technology has resulted in improvement in agricultural production. Recent advancements in technology-enabled crop improvement by allowing inefficiently targeted modification in most of the crops. Owing to the several advantages such as increased resistivity to weather changes, improved shelf life the application of this technology in the agriculture field is expected to increase in the coming years.

End-use Insights

The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 48.8% in 2020. Pharmaceutical companies are increasingly adopting CRISPR-Cas9 to create better biological models for human diseases in less time and further accelerate the identification & validation of new therapeutic targets. Thus, the presence of a huge clinical pipeline based on the CRISPR gene-editing technology is expected to boost the market growth.

Moreover, as cell and gene therapies are gaining momentum, there is a high demand for CRISPR-based gene-editing techniques for the development of novel therapies. Owing to this, contract research organizations are expected to witness substantial market growth in the forecast period. Intensive competition among players with a focus on time and cost reduction is expected to influence demand for CRISPR in this segment.

Modifications in CRISPR’s basic architecture have extended its reach into epigenome, thereby offering control of the epigenetic inheritance. For instance, in April 2021 researchers from the University of California, and the Massachusetts Institute of Technology developed a CRISPR on-off switch to control gene expression.

Regional Insights

North America dominated the CRISPR and Cas genes market and accounted for the largest revenue share of 38.4% in 2020. The expanding biopharmaceutical R&D coupled with the active engagement of various pharmaceutical companies in the development of novel therapies by implementing genome editing tools has significantly contributed to the dominance of the region. Moreover, the U.S. has the largest number of CRISPR publications representing extensive research in the region.

In Asia Pacific, the market is projected to witness the fastest growth throughout the forecast period. This can be attributed to the increasing number of ongoing clinical trials and expanding research in gene editing tools in the region. Also, the growing popularity of CRISPR technology in Asian countries such as China and Japan is expected to further support the growth of the market in the region.

In March 2021, Dublin-based ERS Genomics granted CRISPR-Cas9 patent to a Japanese biotech startup - Setsuro Tech. The Japanese company is developing cell and animal models based on this technology. Such initiatives are anticipated to increase the adoption of CRISPR-Cas9 technology in the country leading to significant revenue generation in the near future.

Key Companies & Market Share Insights

The market is witnessing increased competition given the technological advancements and broadened application landscape. This has triggered the entry of new players in this arena further intensifying the competition. These companies are collaborating with global players to develop new product lines and enhance their market presence. In April 2021, CRISPR Therapeutics and Vertex Pharmaceuticals, Inc. amended their collaboration agreement for the development of a CRISPR/Cas9-based gene editing therapy - CTX001. This therapy can be used to treat transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD). Some of the prominent players in the CRISPR and Cas Genes market include:

• AstraZeneca plc.

• Addgene

• Caribou Biosciences, Inc.

• Cellectis, CRISPR Therapeutics

• Editas Medicine, Inc.

• eGenesis

• F. Hoffmann-La Roche Ltd.

• Horizon Discovery Group plc

• GenScript

• Danaher Corporation

• Intellia Therapeutics, Inc.

• Lonza

• Merck KGaA

• Intellia Therapeutics, Inc.

• Takara Bio Inc.

• Thermo Fisher Scientific, Inc.

• Synthego

• Mammoth Biosciences

• Inscripta, Inc.

• Cibus

• Beam Therapeutics

• PLANTeDIT

• Vertex Pharmaceuticals Incorporated

• Hera BioLabs

• OriGene Technologies, Inc.

• Recombinetics, Inc.

CRISPR And Cas Genes Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global CRISPR and Cas genes market report on the basis of product and service, application, end-use, and region:

• Product & service Outlook (Revenue, USD Million, 2017 - 2028)

  • By Product

    • Kits & Enzymes

      • Vector-based Cas

      • DNA-free Cas

    • Libraries

    • Design Tool

    • Antibodies

    • Others

  • By Service

    • Cell Line Engineering

    • gRNA Design

    • Microbial Gene Editing

    • DNA Synthesis

• Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Biomedical

    • Genome Engineering

    • Disease Model Studies

    • Functional Genomics

    • Epigenetics

    • Others

  • Agricultural

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Biotechnology & Pharmaceutical Companies

  • Academics & Government Research Institutes

  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • Italy

    • Spain

    • U.K.

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia